OCT 15, 2016 05:56 AM PDT

Brain Tumors: How Surgeons are Operating on the Inoperable

WRITTEN BY: Xuan Pham
Glioblastomas are notorious for being inoperable. That’s why when scientists developed a laser method to “cook” the tumor from the inside, they thought it was game-over for the malignant cancer. However, doctors soon discovered other problems – the tumor became swollen and endangered patients in other ways. Now, a combination technique may finally make it possible to effectively treat and remove the cancer.
 
Dubbed as the “octopus tumor,” GBMs are characterized with malignant glial cells forming vast networks of tendrils throughout the brain. This makes it nearly impossible to surgically remove all the cancerous tissues. As such, this brain cancer can evade even the most aggressive surgeries, chemotherapies, and radiotherapies, leaving patients with a five-year survival rate of less than 10 percent.
 
In 2013, Andrew Sloan and his colleagues pioneered a technique to treat the “inoperable” tumor. Since it would be difficult to remove it with conventional scalpels, Sloan and his team thought to kill the tumor by heating it up from the inside. They team developed a technique known as laser interstitial thermotherapy (LITT), which targets the laser to the tumor via a small hole in the scalp.
 
While LITT was successful at attacking the tumor, doctors soon found that the treatment led to swelling. This was especially dangerous for large tumors, where the deep swelling could seriously jeopardize a patient’s health.
 
So the surgeons had no choice but to operate on the inoperable. But in the course of this procedure, Dr. Sloan made a starling realization: the swollen, cooked tumor was mushy instead dense, and clean instead of bloody – the heat had apparently cauterized the tumor’s blood supply. This state of the tumor was amenable to being “sucked out” through a small hole in the skull, a craniotomy.
 

"I am very excited by the results of this study. This procedure is a new option for patients with these large malignant tumors," said Andrew Sloan, surgeon at the University Hospitals Case Medical Center, and lead author of the new study. "We have seen similar results and overall survival compared to LITT procedures performed in patients with smaller lesions and with lower risk."
 
The team has since performed this combination technique on 10 patients with extremely aggressive and intractable brain tumors, with promising results. Of the 10 patients, 6 remain alive with a median progression-free survival of 280 days, and a median overall survival of 482 days.
 
"We feel with further studies, LITT will continue to develop into a safer, more user-friendly technique that may help remove more of these deadly tumors than surgery alone can accomplish," said Sloan.

Additional sources: MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 27, 2018
Clinical & Molecular DX
APR 27, 2018
Stomach Pain Is A Warning Sign for Meningitis
Simply looking out for the classic warning signs of a meningococcal infection may cause some cases to go unnoticed - at first. A new study from the Institu...
MAY 01, 2018
Clinical & Molecular DX
MAY 01, 2018
Ditching Mammograms for Dye-Based Breast Cancer Diagnosis
Move over, mammograms. University of Michigan scientists have a new solution for diagnosing breast cancer that’s possibly more accurate, less invasiv...
MAY 16, 2018
Clinical & Molecular DX
MAY 16, 2018
Malaria Changes the Way You Smell
Malaria is a lethal disease caused by a parasitic infection. However, some people carry the malaria parasite without ever showing signs of the disease. Thi...
MAY 22, 2018
Cancer
MAY 22, 2018
Novel PD-L1/TGF-ß Fusion Protein for HPV-Associated Cancers Enters Phase II Clinical Trial
Novel PD-L1/TGF-ß fusion protein for HPV-associated cancers enters phase II clinical trial. Oncology researchers excited about the potential of this bi-functional protein to combat cancer...
JUN 27, 2018
Clinical & Molecular DX
JUN 27, 2018
Are High-Strength MRIs Releasing Mercury from Dental Fillings?
A super strong MRI approved by the U.S. Food and Drug Administration (FDA) may be releasing dangerous amounts of mercury from tooth fillings. From Akdeniz...
JUL 03, 2018
Clinical & Molecular DX
JUL 03, 2018
Blood Test Deciphers Your Internal Rhythm
A personalized reading of your circadian rhythm could help scientists prescribe the exact time of day that drug treatments will be the most effective. A ne...
Loading Comments...